AIM ImmunoTech

AIM ImmunoTech Equity

The The Equity of AIM ImmunoTech (AIM) as of Oct 12, 2026 is -9.78 M USD. In the previous year, The Equity was -1.32 M USD — a change of 640.02% (lower).

Equity

-9.78 MUSD

YoY

640.02%

Last updated:

In 2025, AIM ImmunoTech's equity was -9.78 M USD, a 640.02% increase from the -1.32 M USD equity in the previous year.

The AIM ImmunoTech Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
5.17 M USD
Jan 1, 2019
12.91 M USD
Jan 1, 2020
61.29 M USD
Jan 1, 2021
56.88 M USD
Jan 1, 2022
38.47 M USD
Jan 1, 2023
10.23 M USD
Jan 1, 2024
-1.32 M USD
Jan 1, 2025
-9.78 M USD
The AIM ImmunoTech Equity history
YEAREquityYoY
-9.78 MUSD+640.02%
-1.32 MUSD-112.92%
10.23 MUSD-73.40%
38.47 MUSD-32.37%
56.88 MUSD-7.20%
61.29 MUSD+374.89%
12.91 MUSD+149.46%
5.17 MUSD-40.55%
8.70 MUSD-43.84%
15.50 MUSD-23.92%
20.37 MUSD-18.53%
25.00 MUSD—
Access this data via the Eulerpool API
Get Free API Key

AIM ImmunoTech Stock analysis

What does AIM ImmunoTech do? AIM ImmunoTech is one of the most popular companies on Eulerpool.

Equity Details

Analyzing AIM ImmunoTech's Equity

AIM ImmunoTech's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding AIM ImmunoTech's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating AIM ImmunoTech's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

AIM ImmunoTech's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in AIM ImmunoTech’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about AIM ImmunoTech stock

The Equity of AIM ImmunoTech is -9.78 M USD in 2025.

The Equity of AIM ImmunoTech changed from -1.32 M USD to -9.78 M USD, representing a 640.02% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity AIM ImmunoTech since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's AIM ImmunoTech historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — AIM ImmunoTech

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — AIM ImmunoTech